Research Radartracking 1,762 published studies Β· 471 human Β· 11 safety signals Β· 58 clinical trials Β· 44 cancer pages Β· updated Sep 2026Open the Research Map β†’

Uterine Serous Carcinoma

A plain-English summary of the published research on Uterine Serous Carcinoma, reviewed and approved by our editors β€” not a hand-curated clinical overview.

Research summary Β· reviewed
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Jun 2026 Β· OncoForge editorial Β· How we review β†’

AI extractedhuman reviewedsources checkedretractions suppressedΒ· last updated Jun 2026

Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
81 published studies that name Uterine Serous Carcinoma39 human studies approved & graded (trial, observational, or meta-analysis)34 human clinical studies in the Uterine Serous Carcinoma corpus367 source documents in the Uterine Serous Carcinoma corpus

last checked June 19, 2026

Why this grade?

Human trial / meta-analysis β€” Includes human trial or meta-analysis evidence.

Computed deterministically from the studies’ types and reported outcomes β€” not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split into standard care, guideline or regulatory options, supportive care, and studied but not standard so established care is not mixed with experimental or supportive items.

Studied, not standard - investigational
  • hysterectomy + surgical staging
  • chemotherapy
  • cisplatin
  • trastuzumab deruxtecan
  • cyclophosphamide
  • doxorubicin
  • Trastuzumab-Deruxtecan (T-Dxd)
  • lenvatinib
  • pembrolizumab
  • paclitaxel
  • carboplatin
  • olaparib
  • sulfasalazine

Read the guidelines

Cancer-specific deep links aren’t curated yet β€” these search the authoritative sources for Uterine Serous Carcinoma.

Treatment map: Uterine Serous Carcinoma

Open as a full page β†’

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works β€” confirm anything here with your oncology team.

13
Interventions
0
Standard of care
5
Tested in people
6
Lab / animal
2
Named in lit.
5
Classes
Standard of care (0) Guideline option (0) Tested in people (5) Lab / animal only (6) Named in the literature (2)

Tested in people, by trial phase: phase not reported Γ—5

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
β€”
β€”
β€”
β€”
1
Chemotherapy
β€”
β€”
3
2
1
Targeted therapy
β€”
β€”
2
2
β€”
Immunotherapy
β€”
β€”
β€”
1
β€”
Repurposed drugs
β€”
β€”
β€”
1
β€”

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Investigational & adjunct compounds β€” detail (13)
Named in the literature
hysterectomy + surgical stagingchemotherapy

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA βœ“" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Get cited updates on Uterine Serous Carcinoma
A monthly email when the research changes β€” $10/mo. Manage follows
Follow Uterine Serous Carcinoma

Snapshot

The essentials in ~60 seconds β€” every line is drawn from the cited sources below.

What it is
Uterine serous carcinoma (often called uterine papillary serous carcinoma when β‰₯25% shows serous differentiation) is a rare, aggressive variant of endometrial cancer that accounts for up to 40% of endometrial cancer deaths and is frequently diagnosed at advanced stage. [1][2]
Survival
Prognosis is generally poor and stage-dependent: three-year survival was 81% for revised stage I, 52% for stage II, 46% for stage III, and 19% for stage IV. Reported 5-year overall survival was stage I 46%, stage II 67%, stage III 34%, and stage IV 29%. [3][1]
Standard treatment
Meticulous surgical staging at the time of hysterectomy is recommended; optimal adjuvant therapy is controversial and randomized trials are lacking, and administration of chemotherapy is an independent predictor of survival on multivariate analysis. [4][1][3]
Key test
Assessment for extrauterine disease at presentation (surgical staging) is the most important feature for prognosis and guides management. [4][3]
Biggest challenge
The main challenges are frequent presentation at advanced stage and high recurrence rates, together with uncertainty about optimal adjuvant therapy because randomized trials are lacking. [1][4][3]

Ask about Uterine Serous Carcinoma

Answers come only from the cited sources on this page β€” with the supporting evidence shown. If the sources here don't cover your question, it will say so. Educational information, not medical advice.

Key numbers & factors

Survival by stage

StageSurvivalNotes
stage I5-year OS 46%recurrence rate 41.4% [1]
stage II5-year OS 67%recurrence rate 20% [1]
stage III5-year OS 34%recurrence rate 58.8% [1]
stage IV5-year OS 29%recurrence rate 71.4% [1]

Risk factors

  • β–² increases riskExtrauterine disease β€” most important feature in assessing prognosis [4]
  • β–² increases riskVascular invasion β€” related to poor prognosis [2]

Biomarkers

  • 11-miRNA signature Β· discriminates uterine from ovarian serous carcinoma (diagnostic) [5]

9 sections β€” tap any heading to expand its cited detail. Key points are above.

OverviewUterine serous carcinoma is a rare variant of endometrial carcinoma responsible for up to 40% of endometrial cancer deaths. It is defined when at least 25% of the tumor shows serous differentiation and displays considerable morphologic heterogeneity, including areas resembling clear-cell carcinoma and variations in papillary architecture.3 points
  • Uterine papillary serous carcinoma (UPSC) is a rare variant of endometrial carcinoma responsible for up to 40% of endometrial cancer deaths. [1]
  • The term "uterine serous carcinoma" is used for endometrial neoplasms in which at least 25% of the carcinoma shows serous differentiation because their behavior is similar. [2]
  • Uterine serous carcinomas display considerable morphologic heterogeneity, including areas resembling clear-cell carcinoma and variations in papillary architecture. [2]
EpidemiologyUterine papillary serous carcinoma is an aggressive variant of endometrial cancer with frequent advanced-stage presentation, high recurrence rates, and low overall survival. Synchronous endometrial and ovarian malignancies occur in 5% of women presenting with endometrial cancer and 10% of patients presenting with ovarian malignancy.2 points
  • Synchronous endometrial and ovarian malignancies occur in 5% of women presenting with endometrial cancer and 10% of patients presenting with ovarian malignancy. [5]
  • Uterine papillary serous carcinoma is an aggressive variant of endometrial cancer associated with a high proportion of advanced-stage disease at diagnosis, high recurrence rates, and low overall survival. [1]
Staging & riskSurvival for uterine serous carcinoma varies by stage, with reported three-year survival of 81% for revised stage I, 52% for stage II, 46% for stage III, and 19% for stage IV. Extrauterine disease can be present even without myometrial invasion, some authors classify very limited lesions as "minimal uterine serous carcinoma," and the streamlined 2009 FIGO criteria may not adequately delineate survival for early-stage USC.4 points
  • Three-year survival rate was 81% for revised stage I, 52% for stage II, 46% for stage III, and 19% for stage IV. [3]
  • The streamlined 2009 FIGO criteria do not adequately delineate survival for USC in early-stage disease. [3]
  • Extrauterine disease was observed in 22% of patients without myometrial invasion. [3]
  • The authors regard endometrial intraepithelial carcinoma (EIC) and superficial serous carcinomas (SSC) measuring 1 cm or less as "minimal uterine serous carcinoma." [4]
PrognosisPrognosis for uterine serous carcinoma varies by stage, with higher stage associated with higher recurrence rates and lower long-term survival. Presence of extrauterine disease at presentation is described as the most important prognostic feature, and widespread metastasis, recurrence, and death have been reported even when myometrial invasion was minimal or the tumor was confined to an endometrial polyp.4 points
  • By stage, reported recurrence rates and 5-year overall survival (OS) were: stage I β€” recurrence rate 41.4% and 5-year OS 46%; stage II β€” recurrence rate 20% and 5-year OS 67%; stage III β€” recurrence rate 58.8% and 5-year OS 34%; stage IV β€” recurrence rate 71.4% and 5-year OS 29%. [1]
  • In the Rajavithi Hospital series, the 2-year progression-free survival for UPSC was 95.5% and the 2-year overall survival was 86.7%. [6]
  • The most important feature in assessing prognosis is the presence or absence of extrauterine disease at presentation. [4]
  • Widespread metastasis, recurrence, and death occurred even in cases where myometrial invasion was less than 1 mm or where tumor was confined to an endometrial polyp. [2]
Key biomarkers1 point
  • A panel of 11-miRNA signatures was identified to significantly discriminate between ovarian and uterine serous carcinoma (P < .05). [5]
Standard managementOptimal adjuvant therapy for uterine serous carcinoma (UPSC) is controversial and randomized trials are lacking. Prognostic factors identified on multivariate analysis include new FIGO stage, myometrial invasion, angiolymphatic invasion, and administration of chemotherapy, and some authors recommend meticulous surgical staging for endometrial intraepithelial carcinoma or superficial serous carcinoma at the time of hysterectomy.3 points
  • Controversy remains regarding optimal adjuvant therapy for UPSC, with lack of randomized trials to date. [1]
  • New FIGO stage, myometrial invasion, angiolymphatic invasion, and administration of chemotherapy all remained independent predictors of survival on multivariate analysis (P < 0.05). [3]
  • The authors state that patients with endometrial intraepithelial carcinoma or superficial serous carcinoma should undergo meticulous surgical staging at the time of hysterectomy. [4]
Treatments & compounds studiedTwo therapeutic approaches are reported across the cited studies: a surgical procedure (hysterectomy with surgical staging) and systemic chemotherapy.2 treatments

Chemotherapy

  • chemotherapy: Administration of chemotherapy was an independent predictor of survival on multivariate analysis (P < 0.05). [3]

Procedures & devices

  • hysterectomy and surgical staging: Studies report that patients underwent hysterectomy with surgical staging, and that meticulous surgical staging is recommended for patients with EIC or SSC at the time of surgery. [6][4]
    disease-free at 52 months 93%
    Source quote
    • β€œThirteen of 14 patients (93%) with EIC or SSC confined to the uterus (stage I or IIA) were disease free and one was dead of unrelated causes at 52 months, whereas seven women who presented with extrauterine disease, even if only microscopic, were either dead of disease or alive with recurrences.”
What we don't know yetImportant uncertainties remain for uterine serous carcinoma: optimal adjuvant therapy is unclear and requires randomized trials; staging criteria may need further evaluation; and clinical behavior is variable, with some tumors fatal despite absent myometrial invasion and others cured with surgery alone.3 points
  • Randomized trials are required to clarify optimal adjuvant therapy for patients with uterine serous carcinoma. [1]
  • Further evaluation of more appropriate uterine serous carcinoma staging is warranted. [3]
  • Clinical behavior is variable: some uterine serous carcinomas may prove fatal even when myometrial invasion is apparently absent, whereas others may be cured with surgery alone. [4]
Biology & pathwaysUterine serous carcinoma often has a poor prognosis that is linked to vascular invasion and multifocal carcinogenesis. Intraepithelial carcinoma can be present at multiple genital and peritoneal sites, including the endocervix, fallopian tube, ovarian surface, and peritoneal surfaces or omentum.2 points
  • Poor prognosis in uterine serous carcinoma appeared to be related to a propensity for vascular invasion and multifocal carcinogenesis. [2]
  • Intraepithelial carcinoma was identified at multiple genital and peritoneal sites in the series, including the endocervix, fallopian tube, ovarian surface, and peritoneal surfaces or omentum. [2]

Common questions

What is Uterine Serous Carcinoma?

Uterine serous carcinoma is a rare variant of endometrial carcinoma responsible for up to 40% of endometrial cancer deaths. It is defined when at least 25% of the tumor shows serous differentiation and displays considerable morphologic heterogeneity, including areas resembling clear-cell carcinoma and variations in papillary architecture.

How common is Uterine Serous Carcinoma?

Uterine papillary serous carcinoma is an aggressive variant of endometrial cancer with frequent advanced-stage presentation, high recurrence rates, and low overall survival. Synchronous endometrial and ovarian malignancies occur in 5% of women presenting with endometrial cancer and 10% of patients presenting with ovarian malignancy.

What is the biology of Uterine Serous Carcinoma?

Uterine serous carcinoma often has a poor prognosis that is linked to vascular invasion and multifocal carcinogenesis. Intraepithelial carcinoma can be present at multiple genital and peritoneal sites, including the endocervix, fallopian tube, ovarian surface, and peritoneal surfaces or omentum.

How is Uterine Serous Carcinoma treated?

Optimal adjuvant therapy for uterine serous carcinoma (UPSC) is controversial and randomized trials are lacking. Prognostic factors identified on multivariate analysis include new FIGO stage, myometrial invasion, angiolymphatic invasion, and administration of chemotherapy, and some authors recommend meticulous surgical staging for endometrial intraepithelial carcinoma or superficial serous carcinoma at the time of hysterectomy.

What treatments are studied for Uterine Serous Carcinoma?

Two therapeutic approaches are reported across the cited studies: a surgical procedure (hysterectomy with surgical staging) and systemic chemotherapy.

What is the prognosis for Uterine Serous Carcinoma?

Prognosis for uterine serous carcinoma varies by stage, with higher stage associated with higher recurrence rates and lower long-term survival. Presence of extrauterine disease at presentation is described as the most important prognostic feature, and widespread metastasis, recurrence, and death have been reported even when myometrial invasion was minimal or the tumor was confined to an endometrial polyp.

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked June 19, 2026.

  1. Clinical trialUterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases Β· 2016
  2. Clinical trialUterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features Β· 1992
  3. Clinical trialOutcomes of patients with uterine serous carcinoma using the revised FIGO staging system Β· 2012
  4. Clinical trialMinimal uterine serous carcinoma: diagnosis and clinicopathologic correlation Β· 2000
  5. Clinical trialMicroRNA signatures discriminate between uterine and ovarian serous carcinomas Β· 2018
  6. Clinical trialComparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital Β· 2016

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
3
Meta-analysis
5
Systematic review
1
Randomized trial
2
Clinical trial
44
Observational
0
Case report
46
Review
255
Preclinical
0
Other
11

Living document β€” last change June 19, 2026: Cancer page updated. 2 recent updates logged.

Pooled evidence across studies

PubMed
  • PRAME immunoreactivity rate: 76% (60–90 across studies) Β· PRAME (Preferentially expressed antigen in melanoma)
    13 studies Β· 62% agree Β· moderate35973038
  • Overall HER2 IHC/FISH concordance: 92.5% (91–94 across studies) Β· HercepTestβ„’ + HER2 IQFISH pharmDx (FISH)
    2 studies Β· 100% agree Β· consistent38740270

Numbers pooled deterministically across 44 published studies that passed our figure-accuracy checks β€” a quick synthesis, not a formal meta-analysis. Updated 9/4/2026.

Compounds compared by evidence

PubMed

How to read this: Ranked by the strength and volume of the evidence β€” NOT by how well a treatment works. A higher rank means a compound has been studied more, or in stronger study designs (e.g. randomized trials over lab studies), not that it produces better outcomes. The effect column shows the largest pooled figure reported, not a head-to-head comparison.

#CompoundEvidence strengthStudiesLargest pooled effect
1Trastuzumab Deruxtecan Targeted therapyHuman Β· observational1β€”
2Trastuzumab-Deruxtecan (T-Dxd) Targeted therapyHuman Β· observational1β€”
3Lenvatinib Targeted therapyInsufficient evidence2β€”
4Pembrolizumab ImmunotherapyInsufficient evidence2β€”
5Carboplatin ChemotherapyInsufficient evidence1β€”
6Paclitaxel ChemotherapyInsufficient evidence1β€”

Ranked across 6 compounds with published studies for this cancer. Updated 9/4/2026.

Medicines & supplements studied for Uterine Serous Carcinoma

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Uterine Serous Carcinoma, ranked by how strong the evidence is β€” what studies report, not a recommendation. Tap any to see its full profile.

Medicines Β· 11

CisplatinHuman Β· observationalReported negative1 human1 lab

Human observational evidence only β€” no trials.

Largest credible effect: total_patients 20, n=20 PMID 1526508 Β· effect sizes 1–70 across 12 studies

Most authoritative study: Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer

Effect sizes reported in only 1 of 2 studies.
ChemotherapyFDA off-label2 studiesFull profile β†’
Trastuzumab DeruxtecanHuman Β· observationalReported positive1 human1 animal

Human observational evidence only β€” no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 Β· effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Effect sizes reported in only 1 of 2 studies.
Targeted therapyFDA off-label2 studiesFull profile β†’
CyclophosphamideHuman Β· observationalReported negative1 human

Human observational evidence only β€” no trials.

Largest credible effect: total_patients 20, n=20 PMID 1526508 Β· effect sizes 1–70 across 12 studies

Most authoritative study: Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)

Based on a single study.
ChemotherapyFDA off-label1 studyFull profile β†’
DoxorubicinHuman Β· observationalReported negative1 human

Human observational evidence only β€” no trials.

Largest credible effect: total_patients 20, n=20 PMID 1526508 Β· effect sizes 1–70 across 12 studies

Most authoritative study: Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)

Based on a single study.
ChemotherapyFDA off-label1 studyFull profile β†’
Trastuzumab-Deruxtecan (T-Dxd)Human Β· observationalReported positive1 human

Human observational evidence only β€” no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 Β· effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
Targeted therapy1 studyFull profile β†’
OlaparibAnimal onlyReported positive1 animal

Animal studies only β€” no human data.

Most authoritative study: A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.
Targeted therapyFDA off-label1 studyFull profile β†’
PaclitaxelLab onlyReported positive1 lab

Lab / cell studies only β€” no human or animal data.

Most authoritative study: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

No human studies yet Β· No numeric effect sizes reported.
ChemotherapyFDA off-label2 studiesFull profile β†’
Sulfasalazine †RxLab onlyMixed results1 lab

Lab / cell studies only β€” no human or animal data.

Most authoritative study: Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.
Repurposed drugs1 studyFull profile β†’
LenvatinibInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: response_rate (pembrolizumab + lenvatinib) 50% PMID 36447064

Most authoritative study: Targeted Therapies in the Treatment of Uterine Serous Carcinoma

No human studies yet Β· Effect sizes reported in only 1 of 3 studies.
Targeted therapyFDA off-label3 studiesFull profile β†’
PembrolizumabInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: response_rate (pembrolizumab + lenvatinib) 50% PMID 36447064

Most authoritative study: Targeted Therapies in the Treatment of Uterine Serous Carcinoma

No human studies yet Β· Effect sizes reported in only 1 of 3 studies.
ImmunotherapyFDA off-label3 studiesFull profile β†’
CarboplatinInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.
ChemotherapyFDA off-label1 studyFull profile β†’

What recent studies report in Uterine Serous Carcinoma

These are reviewed studies whose abstracts concern Uterine Serous Carcinoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Uterine Serous Carcinoma. Most are early lab, animal, or small human studies, and findings often conflict.

60 studies32 human3 animal6 lab⚠ Conflicting evidenceMechanism (29)Trial (2)

Tracking 60 published studies of Uterine Serous Carcinoma: 32 in humans, 3 in animals, 6 in the lab, 19 reviews/other.

Reported direction across studies: 36 positive, 10 mixed, 4 negative, 10 inconclusive.

Findings conflict β€” both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether anything works for Uterine Serous Carcinoma.

Compounds with studies mentioning Uterine Serous Carcinoma

Pembrolizumab (3)Lenvatinib (3)Trastuzumab deruxtecan (2)Olaparib (1)Trastuzumab deruxtecan t dxd (1)Sulfasalazine (1)Cisplatin (1)Paclitaxel (1)
Animal studyReported positivePreclinical onlyTier 2 Β· animal

A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma

Molecular cancer therapeutics Β· Sep 2026

Olapaributerine serous carcinoma

This preclinical study tested a novel CDK12 inhibitor (CTX-439) alone and combined with the PARP inhibitor olaparib in uterine serous carcinoma (USC) cell lines and patient-derived xenograft models. CTX-439 suppressed expression of HR-related genes (including BRCA1 and BRCA2), induced DNA damage and apoptosis, inhibited tumor growth in PDX models with high CDK12 expression, and enhanced tumor sensitivity to olaparib. Analysis of genomic datasets found CDK12 amplification more frequent in USC than in high-grade serous ovarian carcinoma, associated with higher CDK12 expression and poorer prognosis, but not with HRD scores.

Studied with: olaparib.

Key findings
  • USC exhibited a higher HRD score than other histologic subtypes of uterine endometrial carcinoma but lower than HGSOC.
  • CDK12 amplification occurred more frequently in USC than in HGSOC but was not associated with HRD scores.
  • Tumors with CDK12 amplification demonstrated high CDK12 expression, which correlated with poor prognosis in USC.
  • The CDK12 inhibitor CTX-439 suppressed HR-related gene expression, including BRCA1 and BRCA2.
  • CTX-439 induced apoptosis and DNA damage in USC models.
  • CTX-439 inhibited tumor growth in USC PDX models with high CDK12 expression.
  • CDK12 inhibition enhanced tumor sensitivity to the PARP inhibitor olaparib in USC PDX models.
Limitations: Preclinical study limited to cell lines and patient-derived xenograft (PDX) models; no human clinical data presented.; Abstract does not report sample sizes, dosing regimens, or toxicity/safety data.; No long-term outcomes or survival data in patients.; Findings from PDX models may not translate to clinical efficacy in humans..

AI summary of the abstract, human-reviewed Β· Sep 2026. Describes what this study reported, not medical advice. View on PubMed

Case reportInconclusiveLimited evidenceTier 3 Β· early humann = 1

Endometrial Serous Carcinoma Arising From Adenomyosis

Cureus Β· May 2026 Β· case report

endometrial serous carcinomauterine serous carcinoma

This paper is a case report of a postmenopausal woman diagnosed with endometrial (uterine) serous carcinoma that arose from adenomyosis. The authors describe diagnostic challenges, clinical management, and prognosis for this single patient and include a literature review to provide broader context.

Key findings
  • Reported a single case of uterine/ endometrial serous carcinoma arising from adenomyosis.
  • Highlights diagnostic challenges when serous carcinoma is associated with adenomyosis.
  • Discusses clinical management and prognosis for the reported patient.
  • Includes a comprehensive review of the literature on this uncommon association.
Limitations: Single-patient case report limits generalizability.; No quantitative outcomes or comparative data reported.; No mechanistic or pathological detail provided in the abstract.; Prognostic implications cannot be inferred from one case..

AI summary of the abstract, human-reviewed Β· Sep 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Human Β· observationalReported positiveLimited evidenceTier 3 Β· early humann = 94

Adjuvant therapy in early uterine serous carcinoma

American journal of epidemiology Β· Jan 2026 Β· retrospective cohort study

uterine serous carcinoma

This retrospective single-institution study identified 94 patients with stage I–II uterine serous carcinoma treated from 2006–2019 and examined associations between adjuvant therapies and outcomes. Most patients received adjuvant therapy, commonly chemotherapy plus vaginal brachytherapy; at median follow-up 33.5 months, 81.9% had no evidence of disease. Patients receiving six cycles of adjuvant chemotherapy had statistically better overall survival (P = .004) and recurrence-free survival (P = .02) compared with those who did not receive adjuvant chemotherapy.

Reported effects: sample_size 94, n=94 Β· median_followup 33.5 mo, n=94 Β· +10 more

Studied with: radiation therapy, vaginal brachytherapy.

Key findings
  • Ninety-four patients were identified.
  • Median follow-up time was 33.5 months.
  • Median age was 68 years (range, 49-87).
  • Most patients (n = 79, 84.0%) received adjuvant therapy; a majority received a combination of systemic chemotherapy and radiation therapy (n = 55, 58.5%), with chemotherapy plus vaginal brachytherapy the most common combination (n = 42, 44.7%).
  • Most patients (n = 77, 81.9%) remained without evidence of disease, while 17 patients (18.1%) recurred.
  • Patients receiving 6 cycles of adjuvant chemotherapy experienced improved overall survival (P = .004) and improved recurrence-free survival (P = .02) compared to those receiving no adjuvant chemotherapy.
Limitations: Retrospective, non-randomized design; Single-institution cohort; Relatively small sample size (n = 94); Potential selection and treatment-allocation bias; Median follow-up of 33.5 months is modest and may limit assessment of long-term outcomes; No chemotherapy regimen details or toxicity data provided in the abstract.

AI summary of the abstract, human-reviewed Β· Sep 2026. Describes what this study reported, not medical advice. View on PubMed

Case reportInconclusiveLimited evidenceTier 3 Β· early humann = 1

Uterine serous carcinoma arising in adenomyosis: a case report

Journal of ultrasound Β· Nov 2025 Β· case report

uterine serous carcinomaendometrial cancer arising in adenomyosisendometrial carcinoma

This is a case report of a 55-year-old postmenopausal woman who was found to have uterine serous carcinoma arising in adenomyosis. Imaging (CT and ultrasound) showed pelvic cystic masses and a 50 Γ— 36 mm subserous cystic-solid uterine mass that was initially misdiagnosed as a degenerating fibroid; postoperative histopathology established the diagnosis. The authors note that a de novo cystic area in adenomyosis in postmenopausal women may suggest malignant transformation and emphasize ultrasound as the first imaging choice for gynecological masses.

Reported effects: CA125 44.86, n=1 Β· tumor_size, n=1

Key findings
  • A 55-year-old postmenopausal woman presented with anorexia, weight loss and mild abdominal pain; pelvic CT showed cystic masses.
  • Serum CA125 was 44.86 u/ml.
  • Transvaginal/transabdominal ultrasound detected a 50 Γ— 36 mm subserous cystic-solid mass that was misdiagnosed preoperatively as a subserous uterine fibroid with cystic degeneration.
  • Postoperative histopathological diagnosis was uterine serous carcinoma arising from adenomyosis.
  • Authors suggest that a de novo cystic area in adenomyosis in postmenopausal women may indicate malignant transformation and present ultrasound images to raise diagnostic awareness.
Limitations: Single case report (n=1), so findings are not generalizable.; No control or comparison group.; Abstract provides limited pathological, immunohistochemical, and follow-up details.; Imaging features described may be nonspecific and susceptible to misdiagnosis.; No data on prevalence, diagnostic performance metrics, or outcomes beyond the single case..

AI summary of the abstract, human-reviewed Β· Sep 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismInconclusiveLimited evidenceTier 3 Β· early human

HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma

Cells Β· Aug 2025 Β· review

uterine serous carcinomaendometrial cancerbreast cancer

This is a narrative review of HER2/neu as a signaling and therapeutic marker in uterine serous carcinoma (USC). It summarizes HER2 expression and amplification in USC, compares USC HER2 features to breast cancer, evaluates preclinical and clinical evidence for HER2-directed therapies (including monoclonal antibodies and ADCs), and discusses possible mechanisms of resistance.

Studied with: monoclonal antibodies, antibody-drug conjugates, chemotherapy.

Key findings
  • HER2/neu coordinates cell growth and differentiation and when overexpressed and/or amplified its downstream tyrosine kinase can become constitutively activated, causing dysregulated gene transcription.
  • HER2/neu has been successfully targeted in breast cancer with monoclonal antibodies and antibody-drug conjugates.
  • Use of HER2-directed therapies in gynecologic malignancies has been slower, in part due to unique characteristics of HER2 protein expression and gene amplification in USC such as major heterogeneity and lack of apical staining compared to breast cancer.
  • Optimal testing algorithms for HER2/neu status in USC may have important implications for developing targeted therapies.
  • The review evaluates efficacy of HER2-directed therapies in both preclinical and clinical settings and discusses possible mechanisms of resistance.
Limitations: Narrative review rather than original experimental or systematic/meta-analytic data.; Abstract contains no quantitative results or study-level sample sizes.; Conclusions depend on heterogeneous preclinical and clinical studies in the literature rather than a single controlled dataset.; Field limitations noted (e.g., heterogeneity of HER2 expression in USC) may limit generalizability of testing and therapeutic approaches..

Reviews HER2/neu expression and the potential of HER2-directed therapies in uterine serous carcinoma, with attention to diagnostic testing and resistance.

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Human Β· observationalMechanismReported positiveLimited evidenceTier 3 Β· early humann = 8

Clinicopathologic and Genomic Analysis of Uterine Serous Carcinomas Arising From Endometrial Hyperplasia

The American journal of surgical pathology Β· Apr 2025 Β· retrospective molecular cohort study

uterine serous carcinomaendometrial hyperplasia

Researchers identified 8 uterine serous carcinomas with concurrent endometrial hyperplasia and performed tumor-normal panel sequencing on the carcinoma and hyperplasia separately. In 7 of 8 paired cases the carcinoma and hyperplasia were clonally related and often shared TP53 mutations; one case was genetically unrelated and another shared only a single mutation. ARID1A mutations were more common in hyperplasia-associated USC than in atrophy-associated USC (43% vs 0%; P = 0.02).

Reported effects: cases_screened_with_sequencing_and_slides_available 267, n=267 Β· cases_with_sufficient_tissue_for_molecular_studies 8, n=8 Β· +5 more

Key findings
  • Of 267 USCs with available sequencing and slides, 8 cases with concurrent carcinoma and hyperplasia had sufficient tissue for molecular study.
  • In 7 of these 8 cases (87.5%), USC and hyperplasia were clonally related and shared multiple mutations.
  • TP53 hotspot mutations were shared between carcinoma and hyperplasia in 4 cases (57% of the clonally related cases).
  • In 1 case (USC4) the carcinoma and hyperplasia were genetically unrelated and the hyperplasia was TP53 wild-type.
  • In another case (USC5) the carcinoma and TP53 wild-type hyperplasia shared 1 of 11 mutations and were distinct at the copy number level.
  • ARID1A mutations were more prevalent in hyperplasia-associated USC than in atrophy-associated USC (43% vs. 0%; P = 0.02).
Limitations: Very small molecular cohort (only 8 cases with sufficient tissue) limits generalizability.; Retrospective selection of cases and requirement for sufficient tissue may introduce selection bias.; No functional experiments to demonstrate causality or biological consequences of shared mutations.; Clinical outcome data and broader validation cohorts are not reported in the abstract..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismMixed resultsLimited evidenceTier 4 Β· clinicaln = 95

Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review

Current oncology (Toronto, Ont.) Β· Apr 2025 Β· systematic review

uterine serous carcinoma

This systematic review searched PubMed/Medline and Cochrane through February 2025 and included 95 studies of uterine serous carcinomas. The authors report that these tumors are characterized by TP53 mutations and extensive copy number alterations and are commonly classified in the copy number-high/p53abn molecular group. The review identified 66 distinct molecular characteristics and new cancer signatures that may have prognostic significance and could inform tailored treatment strategies, though these findings require further validation.

Reported effects: included_studies 95 Β· distinct_molecular_characteristics 66

Key findings
  • Uterine serous carcinomas are an aggressive minority of endometrial cancers.
  • These tumors are characterized by mutations in TP53 and extensive copy number alterations and are primarily classified in the copy number-high/p53abn molecular prognostic group.
  • The systematic review searched PubMed/Medline and Cochrane databases through February 2025 and included 95 studies.
  • A total of 66 distinct molecular characteristics and new cancer signatures with potential prognostic impact were identified across the included studies.
  • Authors suggest these molecular findings may inform clinical practice and aid development of tailored treatment strategies for patients with uterine serous carcinoma.
Limitations: Review limited to English-language articles (English-only search was performed).; Systematic review format reported; no pooled meta-analytic effect sizes or patient-level pooled estimates are presented in the abstract.; Prognostic markers and new signatures identified across multiple studies may be heterogeneous and require independent validation before clinical application.; Abstract does not report the quality assessment of included studies or patient-level sample sizes..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Human Β· observationalMechanismReported positiveLimited evidenceTier 3 Β· early humann = 195

Loss of GATA2 promotes invasion and predicts cancer recurrence and survival in uterine serous carcinoma

JCI insight Β· Apr 2025 Β· retrospective multiinstitutional cohort

uterine serous carcinomauterine neoplasm

Researchers scored GATA2 protein levels by immunohistochemistry in a retrospective cohort of 195 uterine serous carcinomas and related GATA2 levels to clinical outcomes. They found that FIGO stage I tumors with high GATA2 (GATA2hi) had 100% recurrence-free and 100% cancer-related survival, and among patients who omitted adjuvant chemotherapy, GATA2hi tumors had 100% 5-year recurrence-free survival versus 60% in GATA2lo tumors. In patient-derived USC cells, depletion of GATA2 increased invasion in vitro. The authors propose GATA2 IHC could identify a subgroup (~33%) of stage I patients with greatly reduced recurrence risk.

Reported effects: recurrence-free survival (FIGO stage I, GATA2hi) 100% Β· cancer-related survival (FIGO stage I, GATA2hi) 100% Β· +2 more

Key findings
  • Patients with FIGO stage I GATA2hi USCs had 100% recurrence-free and 100% cancer-related survival, which was significantly better than patients with GATA2lo USCs.
  • In patients for whom adjuvant chemotherapy was omitted, patients with GATA2hi USC had 100% recurrence-free 5-year survival compared with 60% recurrence-free survival in patients with GATA2lo USC.
  • Depletion of GATA2 in patient-derived USC cells increased invasion in vitro.
  • Routine GATA2 IHC identifies 33% of patients with FIGO stage I USC who have a greatly reduced risk of posthysterectomy USC recurrence.
Limitations: Retrospective cohort design (nonrandomized) limits causal inference and is susceptible to selection and unmeasured confounding.; Mechanistic data demonstrating increased invasion were limited to in vitro depletion of GATA2 in patient-derived cells (no in vivo validation).; Abstract does not report follow-up duration, subgroup sizes, confidence intervals, or p-values for the quoted percentages.; No prospective or external validation cohort reported in the abstract to confirm prognostic performance before clinical implementation..

AI summary of the abstract, human-reviewed Β· Sep 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

ReviewMechanismMixed resultsModerate evidenceTier 4 Β· clinical

Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society Β· Mar 2025 Β· Review

uterine serous carcinomauterine carcinosarcoma

This is a narrative review summarizing recent evidence on molecular classification, biomarkers, and new treatment approaches for uterine serous carcinoma and uterine carcinosarcoma. The authors highlight biomarkers such as HER2, TP53, and mismatch repair deficiency/microsatellite instability, discuss circulating tumor DNA and precision-based treatment options, and note survival disparities for non-Hispanic Black and other underserved minority patients. They conclude that continuing to prioritize biomarker-driven therapies and developing novel treatments through clinical trials β€” integrated with surgery and cytotoxic chemotherapy β€” is necessary.

Reported effects: proportion_of_cases 15% Β· proportion_of_deaths 50%

Key findings
  • Uterine serous carcinoma and uterine carcinosarcoma are rare but account for a disproportionate share of endometrial cancer deaths.
  • These subtypes have a high likelihood of metastasis and multisite recurrence and are biologically distinct from other endometrial cancers.
  • The review analyzes the role of biomarkers including HER2, TP53, and mismatch repair deficiency/microsatellite instability and their influence on treatment strategies and surveillance.
  • Circulating tumor DNA (ctDNA) is discussed as a potential tool.
  • Novel precision-based treatment options are described and the authors call for continued development of biomarker-driven therapies through clinical trials.
  • Disparate survival outcomes for non-Hispanic Black and other underserved minority patients are identified, and strategies to improve their outcomes are discussed.
Limitations: Narrative review rather than primary research; no new experimental or trial data presented in the abstract.; Abstract provides no methods, search strategy, or inclusion criteria (potential selection bias).; Rare tumor subtypes mean available evidence is likely limited and heterogeneous (implicit limitation).; No quantitative synthesis (meta-analysis) or new clinical outcome data reported in the abstract..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Human trialReported positiveLimited evidenceTier 4 Β· clinical

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers

NPJ precision oncology Β· Jan 2025 Β· phase I (ongoing)

gynecological cancersovarian canceruterine serous carcinoma

The study examined whether activation of Cyclin E1/CDK2 makes gynecological cancers vulnerable to the WEE1 inhibitor azenosertib. High Cyclin E1 expression in ovarian cancer cell lines (including forced overexpression) produced strong sensitivity to azenosertib, which was also observed in in vivo models of ovarian and uterine serous carcinoma. Models with high Cyclin E1 had higher replication stress and greater responses to azenosertib; the drug synergized with multiple classes of chemotherapy. Early data from an ongoing phase I study showed clinical activity of azenosertib monotherapy in patients with Cyclin E1/CDK2-activated ovarian and uterine serous carcinomas.

Studied with: chemotherapy.

Key findings
  • Ovarian cancer cell lines with high endogenous Cyclin E1 expression or forced overexpression were exquisitely sensitive to azenosertib.
  • The in vitro sensitivity findings extended to in vivo models of ovarian and uterine serous carcinoma.
  • Models with high Cyclin E1 expression showed higher baseline levels of replication stress and enhanced cellular responses to azenosertib treatment.
  • Azenosertib synergized with different classes of chemotherapy and distinct underlying mechanisms were described.
  • Early evidence from an ongoing phase I study demonstrated clinical activity of monotherapy azenosertib in patients with Cyclin E1/CDK2-activated ovarian and uterine serous carcinomas.
Limitations: Clinical evidence is early (phase I, ongoing) and the abstract provides no sample size, outcome metrics, or safety/toxicity details.; In vivo model species and experimental details are not specified in the abstract.; Mechanistic descriptions and the reported synergy with chemotherapy are not quantified in the abstract.; No randomized or controlled clinical data are reported in the abstract..

Identifies Cyclin E1/CDK2 activation as a potential biomarker of sensitivity to WEE1 inhibition in gynecological cancers.

AI summary of the abstract, human-reviewed Β· Aug 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

ReviewMixed resultsLimited evidenceTier 4 Β· clinical

HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions

Medicina (Kaunas, Lithuania) Β· Dec 2024 Β· literature review

uterine serous carcinoma (serous endometrial carcinoma)endometrial cancer

This literature review summarizes current HER2-directed therapies for HER2-positive uterine serous (serous endometrial) carcinoma. The authors note that about one-third of serous endometrial cancers overexpress HER2 or have ERBB2 amplification and that clinical trials combining chemotherapy with anti-HER2 agents (mainly trastuzumab, alone or with pertuzumab) have shown promising results and been incorporated into international guidelines. The review also describes ongoing research into antibody–drug conjugates and tyrosine kinase inhibitors and highlights that acquired resistance and other unmet needs remain.

Studied with: chemotherapy, pertuzumab.

Key findings
  • Approximately one-third of patients with serous endometrial carcinoma may overexpress HER2/neu protein and/or show c-erBb2 (ERBB2) gene amplification.
  • HER2-directed treatments, especially trastuzumab alone or combined with pertuzumab and chemotherapy, have shown promising results in clinical trials and have been incorporated into international guidelines.
  • Antibody-drug conjugates and tyrosine kinase inhibitors targeting HER2 are under active investigation in endometrial cancer.
  • Acquired resistance to HER2-targeted therapies is an important unresolved problem in endometrial cancer and its mechanisms are mostly unknown.
  • Research is exploring earlier use of HER2-directed therapy in this disease.
Limitations: This is a literature review and does not present new primary experimental or trial data.; The abstract does not state this is a systematic review, so selection and synthesis methods are not described in the abstract.; No quantitative effect sizes or detailed trial outcome data are presented in the abstract.; Mechanistic understanding of acquired resistance in endometrial cancer is reported as largely unknown..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Human Β· observationalReported positiveLimited evidenceTier 3 Β· early humann = 10

Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

BMC cancer Β· Dec 2024 Β· retrospective cohort

Trastuzumab-deruxtecan-t-dxdTrastuzumab-deruxtecanendometrial neoplasmsovarian neoplasmscervical neoplasmsuterine carcinosarcomauterine leiomyosarcomauterine serous carcinomaovarian carcinosarcomahigh-grade serous ovarian carcinomamucinous ovarian carcinomasquamous cervical carcinoma

This retrospective single-center study identified 10 patients with HER2-expressing (IHC 2+/3+) recurrent or metastatic gynecological cancers who received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks). The cohort had a median progression-free survival of 5.4 months (95% CI 0.8-9.8). Five patients had a partial response, one had stable disease at 12 weeks, and four had disease progression at initial assessment. Clinical benefit was observed mainly in tumors with HER2 IHC 3+.

Reported effects: median PFS 5.4 mo [0.8–9.8], n=10 Β· partial responses 5, n=10 Β· +2 more

Key findings
  • 10 patients with recurrent/metastatic HER2-expressing gynecological malignancies were treated with T-DXd.
  • Histologies included uterine neoplasms (n=5), cervical squamous carcinoma (n=1) and ovarian cancers (n=4).
  • Median age was 65.4 years (25th-75th percentile, 58.1-75.2 years).
  • HER2 by IHC: 5 patients were 3+ and 5 patients were 2+.
  • Median number of prior therapy lines was 4 (range 2-6); 2 uterine serous carcinoma patients were pretreated with trastuzumab and 4 patients had prior immunotherapy.
  • Dose: T-DXd 5.4 mg/kg IV every 3 weeks until progression/toxicity.
  • Median progression-free survival (PFS) in the cohort was 5.4 months (95% CI 0.8-9.8 months).
  • Responses: 5 patients had partial response (including 2 previously treated with trastuzumab), 1 patient had stable disease at 12 weeks, 4 patients had disease progression at initial assessment.
  • Most patients who derived clinical benefit had HER2 IHC 3+ expression.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract; Potential selection and reporting bias inherent to retrospective series.

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Browse all studies mentioning Uterine Serous Carcinoma β†’

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination β€” a gap, not evidence of no effect. Open a row to see its studies.

CompoundHuman evidenceMechanismSafetyTrial
Cisplatin11β€”β€”
Trastuzumab Deruxtecan11β€”β€”
Cyclophosphamide1β€”β€”β€”
Doxorubicin1β€”β€”β€”
Trastuzumab-Deruxtecan (T-Dxd)1β€”β€”β€”
Lenvatinibβ€”2β€”β€”
Pembrolizumabβ€”2β€”β€”
Paclitaxelβ€”2β€”β€”
Carboplatinβ€”1β€”β€”
Olaparibβ€”1β€”β€”
Sulfasalazine †Rxβ€”1β€”β€”

Study mix

81 published studies by what they were done in. Lab and animal findings often do not carry over to people.

39 Human3 Animal6 Lab33 Review/other
Reported directionReported positive45Mixed results15Reported negative6Inconclusive15

Compounds with reported-positive results in Uterine Serous Carcinoma

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Human evidence

Trastuzumab Deruxtecan2 positive1 human1 animal
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (2)
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Preclinical only: lab / animal (5)
Pembrolizumab2 positive
Limitations: Narrative review rather than primary clinical trial data; no new patient-level data presented in this abstract.; Many discussed agents are investigational and the abstract notes that several trials are ongoing (mature results not presented).; Abstract provides limited quantitative data and no methodological details (search strategy, inclusion criteria) are described.; Heterogeneity and quality of the underlying studies are not detailed in the abstract.; This is a review article summarizing prior studies and does not present new primary patient-level data.; Some clinical evidence cited (e.g., a phase II study) is early-phase and may have limited sample size or non-randomized design..
Cited positive studies (2)
Lenvatinib2 positive
Limitations: Narrative review rather than primary clinical trial data; no new patient-level data presented in this abstract.; Many discussed agents are investigational and the abstract notes that several trials are ongoing (mature results not presented).; Abstract provides limited quantitative data and no methodological details (search strategy, inclusion criteria) are described.; Heterogeneity and quality of the underlying studies are not detailed in the abstract.; This is a review article summarizing prior studies and does not present new primary patient-level data.; Some clinical evidence cited (e.g., a phase II study) is early-phase and may have limited sample size or non-randomized design..
Cited positive studies (2)
Paclitaxel2 positive1 lab
Limitations: In vitro study using cell lines only; no in vivo or clinical data.; Only one parental and one resistant cell line were compared.; No functional or causal experiments reported to prove that altered metabolites cause resistance.; Abstract does not report experimental replicates, doses, or timepoints.; This is a review article and does not present new primary clinical trial data.; The abstract reports genomic findings but provides no quantitative results, sample sizes, or outcome data..
Cited positive studies (2)
Olaparib1 positive1 animal
Limitations: Preclinical study limited to cell lines and patient-derived xenograft (PDX) models; no human clinical data presented.; Abstract does not report sample sizes, dosing regimens, or toxicity/safety data.; No long-term outcomes or survival data in patients.; Findings from PDX models may not translate to clinical efficacy in humans..
Cited positive studies (1)
Carboplatin1 positive
Limitations: This is a review article and does not present new primary clinical trial data.; The abstract reports genomic findings but provides no quantitative results, sample sizes, or outcome data.; No direct evidence of clinical efficacy of targeted agents in USC is provided in the abstract..
Cited positive studies (1)

Evidence at a glance: compounds studied in Uterine Serous Carcinoma

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

CisplatinHuman Β· observationalReported negative1 human1 lab

Human observational evidence only β€” no trials.

Largest credible effect: total_patients 20, n=20 PMID 1526508 Β· effect sizes 1–70 across 12 studies

Most authoritative study: Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer

Effect sizes reported in only 1 of 2 studies.
Trastuzumab DeruxtecanHuman Β· observationalReported positive1 human1 animal

Human observational evidence only β€” no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 Β· effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Effect sizes reported in only 1 of 2 studies.
CyclophosphamideHuman Β· observationalReported negative1 human

Human observational evidence only β€” no trials.

Largest credible effect: total_patients 20, n=20 PMID 1526508 Β· effect sizes 1–70 across 12 studies

Most authoritative study: Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)

Based on a single study.
DoxorubicinHuman Β· observationalReported negative1 human

Human observational evidence only β€” no trials.

Largest credible effect: total_patients 20, n=20 PMID 1526508 Β· effect sizes 1–70 across 12 studies

Most authoritative study: Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)

Based on a single study.
Trastuzumab-Deruxtecan (T-Dxd)Human Β· observationalReported positive1 human

Human observational evidence only β€” no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 Β· effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
OlaparibAnimal onlyReported positive1 animal

Animal studies only β€” no human data.

Most authoritative study: A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.
PaclitaxelLab onlyReported positive1 lab

Lab / cell studies only β€” no human or animal data.

Most authoritative study: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

No human studies yet Β· No numeric effect sizes reported.
Sulfasalazine †RxLab onlyMixed results1 lab

Lab / cell studies only β€” no human or animal data.

Most authoritative study: Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.
LenvatinibInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: response_rate (pembrolizumab + lenvatinib) 50% PMID 36447064

Most authoritative study: Targeted Therapies in the Treatment of Uterine Serous Carcinoma

No human studies yet Β· Effect sizes reported in only 1 of 3 studies.
PembrolizumabInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: response_rate (pembrolizumab + lenvatinib) 50% PMID 36447064

Most authoritative study: Targeted Therapies in the Treatment of Uterine Serous Carcinoma

No human studies yet Β· Effect sizes reported in only 1 of 3 studies.
CarboplatinInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.

What the research shows for Uterine Serous Carcinoma

A plain-language summary of the reviewed studies OncoForge tracks for Uterine Serous Carcinoma. It reports what those studies described, not a claim that any compound or therapy helps or harms Uterine Serous Carcinoma. Most of this evidence is early, and findings often conflict.

  • Molecular profiling studies and narrative reviews identify distinct molecular subtypes in endometrial cancers and highlight biomarkers relevant to uterine serous carcinoma (USC), including frequent TP53 alterations and HER2 overexpression in a subset of cases.
  • A narrative review and molecular analyses note that a p53 signature is commonly observed in older women and has been proposed as an early marker associated with USC development.
  • A small retrospective single-center study treated patients with HER2-expressing recurrent or metastatic gynecologic cancers (including endometrial neoplasms) with trastuzumab deruxtecan and reported a median progression-free survival of 5.4 months for the cohort.
  • Overall the literature for USC in these reports is heterogeneous and composed primarily of molecular characterizations, narrative reviews, and limited observational clinical data rather than randomized trials.

Compounds studied in Uterine Serous Carcinoma

Trastuzumab Deruxtecan1 study
In a small, retrospective single-center cohort of HER2-expressing recurrent or metastatic gynecologic cancers (including endometrial neoplasms), patients received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks) and the group had a median progression-free survival of 5.4 months; evidence is limited by the small sample size, retrospective design, and inclusion of mixed gynecologic tumor types rather than a USC-only population.

Supportive & alternative options discussed

  • Exercise / prehabilitation: Also discussed as a supportive option for people with uterine cancers to help maintain physical function and quality of life during and after treatment.
  • Acupuncture: Also discussed as a supportive option for symptom management (for example, pain or nausea) in people with gynecologic cancers.
  • Mind–body (MBSR / CBT): Also discussed as a supportive option to address psychological distress, coping, and overall well-being in people with uterine cancers.

What we don’t know yet

  • Are there prospective or randomized clinical trial data showing benefit of HER2-targeted antibody–drug conjugates specifically in uterine serous carcinoma?
  • What is the activity and safety of trastuzumab deruxtecan in a USC-only population, and which patients (by HER2 testing method or level) are most likely to benefit?
  • What are optimal dosing, sequencing, and combination strategies for HER2-directed therapies in USC?
  • What are the long-term outcomes and potential late toxicities of trastuzumab deruxtecan in gynecologic cancers, including USC?
  • How do other molecular biomarkers (beyond HER2 and TP53) influence prognosis and response to targeted therapies in USC?
The evidence base is preliminary and heterogeneousβ€”largely molecular studies, reviews, and small retrospective cohortsβ€”so clinical effects and optimal use of HER2-targeted agents in uterine serous carcinoma remain unestablished.

Clinical trials in Uterine Serous Carcinoma

37 ongoing Β· 58 completed Β· tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive β€” read the results. Not a recommendation.

Completed
20 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov β†’

Getting care & support

Nonprofit / Gov

Practical, vetted help for Uterine Serous Carcinoma β€” advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet β€” these general organizations can help in the meantime.

Financial help

  • PAN Foundation β†— β€” Copay assistance funds by diagnosis (funds open and close as money allows). Β· status changes often β€” check the fund’s site
  • HealthWell Foundation β†— β€” Copay and premium assistance funds by disease. Β· status changes often β€” check the fund’s site
  • CancerCare β€” financial assistance β†— β€” Limited grants plus free financial counseling. Β· status changes often β€” check the fund’s site
  • Family Reach β†— β€” Help with everyday living costs (rent, transport, food) during treatment. Β· status changes often β€” check the fund’s site
  • NeedyMeds β†— β€” Searchable directory of drug patient-assistance and discount programs. Β· status changes often β€” check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details β€” your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) β€” most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance β€” each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources β€” never product sellers β€” and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Interactions & safety to check: Uterine Serous Carcinoma

This is not a complete interaction check. It only covers the compounds we track and the signals reported in studies. A drug or supplement not listed here is not therefore safe. Bring your full medication and supplement list to your pharmacist and oncologist before changing anything.

Potential interactions: highest-stakes first

Safety considerations

Heading to an appointment? Get a printable one-page summary β€” studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment β†’